Evidence map›Paper›PMID 34727107›Full record

ArticlePLoS medicine2021

Epidemiology of type 2 diabetes remission in Scotland in 2019: A cross-sectional population-based study.

Mireille Captieux, Kelly Fleetwood, Brian Kennon, Naveed Sattar, Robert Lindsay, Bruce Guthrie, Sarah H Wild, Scottish Diabetes Research Network Epidemiology Group

Abstract read
In one paragraph

Article in PLoS medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Clinical and Metabolic Characteristics of Spontaneous Remission in Type 2 Diabetes: A Real-World Study from South India.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Recent progress of remission in type 2 diabetes.Therapeutic advances in endocrinology and metabolism · 2025
    Review
  9. Mortality attributable to diabetes in Cuba: Estimates for 2019.Public health in practice (Oxford, England) · 2024
    Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. The Role of Beta Cell Recovery in Type 2 Diabetes Remission.International journal of molecular sciences · 2022
    Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mireille CaptieuxUsher Institute, The University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0002-4367-9274
Kelly FleetwoodUsher Institute, The University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0002-1382-3095
Brian KennonQueen Elizabeth University Hospital, Glasgow, United Kingdom.ORCID 0000-0002-4963-5870
Naveed SattarInstitute of Cardiovascular and Medical Sciences, The University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0002-1604-2593
Robert LindsayInstitute of Cardiovascular and Medical Sciences, The University of Glasgow, Glasgow, United Kingdom.
Bruce GuthrieUsher Institute, The University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0003-4191-4880
Sarah H WildUsher Institute, The University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0001-7824-2569
Scottish Diabetes Research Network Epidemiology Group

Funding

Chief Scientist Office CAF/18/12
6 · The paper itself

Abstract

backgroundClinical pathways are changing to incorporate support and appropriate follow-up for people to achieve remission of type 2 diabetes, but there is limited understanding of the prevalence of remission in current practice or patient characteristics associated with remission. METHODS AND

findingsWe carried out a cross-sectional study estimating the prevalence of remission of type 2 diabetes in all adults in Scotland aged ≥30 years diagnosed with type 2 diabetes and alive on December 31, 2019. Remission of type 2 diabetes was assessed between January 1, 2019 and December 31, 2019. We defined remission as all HbA1c values <48 mmol/mol in the absence of glucose-lowering therapy (GLT) for a continuous duration of ≥365 days before the date of the last recorded HbA1c in 2019. Multivariable logistic regression in complete and multiply imputed datasets was used to examine characteristics associated with remission. Our cohort consisted of 162,316 individuals, all of whom had at least 1 HbA1c ≥48 mmol/mol (6.5%) at or after diagnosis of diabetes and at least 1 HbA1c recorded in 2019 (78.5% of the eligible population). Over half (56%) of our cohort was aged 65 years or over in 2019, and 64% had had type 2 diabetes for at least 6 years. Our cohort was predominantly of white ethnicity (74%), and ethnicity data were missing for 19% of the cohort. Median body mass index (BMI) at diagnosis was 32.3 kg/m2. A total of 7,710 people (4.8% [95% confidence interval [CI] 4.7 to 4.9]) were in remission of type 2 diabetes. Factors associated with remission were older age (odds ratio [OR] 1.48 [95% CI 1.34 to 1.62] P < 0.001) for people aged ≥75 years compared to 45 to 54 year group), HbA1c <48 mmol/mol at diagnosis (OR 1.31 [95% CI 1.24 to 1.39] P < 0.001) compared to 48 to 52 mmol/mol), no previous history of GLT (OR 14.6 [95% CI 13.7 to 15.5] P < 0.001), weight loss from diagnosis to 2019 (OR 4.45 [95% CI 3.89 to 5.10] P < 0.001) for ≥15 kg of weight loss compared to 0 to 4.9 kg weight gain), and previous bariatric surgery (OR 11.9 [95% CI 9.41 to 15.1] P < 0.001). Limitations of the study include the use of a limited subset of possible definitions of remission of type 2 diabetes, missing data, and inability to identify self-funded bariatric surgery.

conclusionsIn this study, we found that 4.8% of people with type 2 diabetes who had at least 1 HbA1c ≥48 mmol/mol (6.5%) after diagnosis of diabetes and had at least 1 HbA1c recorded in 2019 had evidence of type 2 diabetes remission. Guidelines are required for management and follow-up of this group and may differ depending on whether weight loss and remission of diabetes were intentional or unintentional. Our findings can be used to evaluate the impact of future initiatives on the prevalence of type 2 diabetes remission.

Indexed as

AdultAgedAged, 80 and overCross-Sectional StudiesDiabetes Mellitus, Type 2FemaleGlycated HemoglobinHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioPrevalenceRemission InductionScotlandGlycated Hemoglobin

Identifiers

PMID34727107
PMCPMC8562803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.